2Kirik D, Georgievska B, Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease[J]. Nat Neurosci,2004 ,7(2):105-110.
3Eslamboli A, Cummings RM, Ridley RM, et al. Recombinant adeno- associated viral vector(rAAV) delivery of GDNF provides protection against 6 - OHDA lesion in the common marmoset monkey [J]. Exp Neurol, 2003,184(1):536-548.
4Eslamboli A, Georgievska B, Ridley RM, et al. Continuous Low- Level Glial Cell Line- Derived Neurotrophic Factor Delivery Using Recombinant Adeno - Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease [J]. J Neurosci, 2005, 25 (4) : 769-777.
5Minguez CA, Eseamilla SF. Cell therapy and other neuroregenerative strategies in Parkinson's disease (Ⅱ)[J]. Rev Neurol,2005,41(11) :684-693.
6Behrstock S, Svendsen CN. Combining Growth Factors,Stem Cells,and Gene Therapy for the Aging Brain[J].Ann. N. Y. Aead. Sci,2004,1019(7) :5-14.
7Akerud P, Canals JM, Snyder EY, et al. Neuroprotection through delivery of glial cell line derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease [J]. J Neurosci,2001 ,21(20):8108-8118.
8Dietz GP, Valbuena PC, Dietz B, et al. Application of a blood- brain- barrier- penetrating form of GDNF in a mouse model for Parkinson's disease[J]. Brain Res,2006,1082(1) : 61-66.
9Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line derived neurotrophic factor in Parkinson disease[J]. Nat Med ,2003, 9(5): 589-595.
10Slevin JT, Gash DM, Smith CD, et al. Unilateral intraputaminal glial cell line derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal [J]. Neurosurg Focus,2006,20(5) : E1.
5Yamamoto M, Uesugi T,Nakayama T. Dopamine agonists and cardiacval vulopathyin parkinson disease: a case control study [J]. Neurology, 2006;67(7): 1225-1229.
6Roth J, Ulmanova 0, Ruzicka E. Organ changes induced by ergot derivativedopamine agonist drugs: time to change treatment guidelines in Parkinson’ sdisease? [J]. CasLek Cesk, 2005; 14(4): 123-126.
7Peter L, Lonni S, Peggy A, et al. CSF xanthine, homovanillic acid, and their ratioas biomarkers of Parkinson’ s disease[J]. Brain Research, 2011;1408(23): 88-97.
8Maren C, Kathrin R, Felice G, et al. Early Parkinson' s disease: Longitudinalchanges in brain activity during sequence leaming[J]. Neurobiology of Disease,2010;37(2): 455-460.
